Skip to main content
TipRanks
Go Ultimate75% OFF

KOREA UNITED PHARM, INC. (033270) AI Stock Analysis

KR:033270

KOREA UNITED PHARM, INC.

(Korea Exchange:033270)

Select Model
Rating:71Outperform
Price Target:KRW 17,978.00â–²(15.32% Upside)
Action:initiatedcoverage
Date:10/28/26

The score is primarily supported by strong financial strength (very low leverage, improved profitability, and solid operating cash flow coverage) and compelling valuation (very low P/E and a ~3.75% dividend yield). These positives are meaningfully offset by weak technicals, with the stock trading below major moving averages and showing negative momentum signals.

Positive Factors
Very low leverageThe exceptionally low debt burden gives Korea United Pharm meaningful financial resilience and flexibility. Limited leverage reduces pressure from interest obligations, supports continued investment in pharmaceutical activities, and leaves greater capacity to withstand operating volatility or pursue growth opportunities.
Negative Factors
Volatile margin historyThe recent profitability improvement has not yet demonstrated consistent durability because margins have varied materially across reporting periods and return on equity previously weakened. Such volatility can make future earnings power less predictable and may reflect changing mix, one-offs, or cyclical effects.

KOREA UNITED PHARM, INC. (033270) vs. SPDR S&P 500 ETF (SPY)

-20%-15%-10%-5%0%5%10%15%20%KR:033270-16.11%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
KRW 247.27B
Dividend Yield
3.91%
Average Volume (3M)
32.28K
Price to Earnings (P/E)
4.4
Beta (1Y)
0.09
Revenue Growth
0.85%
EPS Growth
25.23%
Country
KR
Employees
936
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

KOREA UNITED PHARM, INC. Business Overview & Revenue Model

Company Description

Korea United Pharm Inc. is a South Korean enterprise dedicated to the development, production, and distribution of a wide array of pharmaceutical products. The company's extensive portfolio encompasses therapeutic solutions for various medical fields...

KOREA UNITED PHARM, INC. Financial Statement Overview

Summary

Strong overall fundamentals driven by very low leverage (debt-to-equity ~0.03) and improved returns (TTM ROE ~16.6%). Profitability has stepped up materially (TTM net margin ~25.6%, operating margin ~18.0%), and operating cash flow covers earnings well (~1.54x net income). Main risk is volatility in margins and free cash flow consistency across years, which raises sustainability questions.

Income Statement

84Very Positive

Balance Sheet

90Very Positive

Cash Flow

78Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue298.08B288.76B288.71B278.94B262.52B221.04B
Gross Profit175.93B175.41B163.97B158.98B145.29B122.66B
EBITDA65.18B60.47B57.84B70.78B62.05B46.90B
Net Income76.16B38.31B32.45B48.26B45.28B28.65B
Balance Sheet
Total Assets570.76B519.49B473.93B468.86B417.89B380.03B
Cash, Cash Equivalents and Short-Term Investments178.56B157.07B132.32B151.05B142.63B123.20B
Total Debt14.86B14.02B15.65B40.34B30.30B32.99B
Total Liabilities73.13B64.82B67.72B90.18B80.03B79.32B
Stockholders Equity497.12B454.63B406.21B378.68B337.86B300.71B
Cash Flow
Free Cash Flow41.32B27.70B5.57B19.34B39.57B31.30B
Operating Cash Flow83.93B51.14B26.79B50.65B63.78B44.09B
Investing Cash Flow-60.40B-41.07B11.70B-56.41B-87.90B-17.70B
Financing Cash Flow-4.62B-3.63B-29.46B2.55B-10.59B-8.20B

KOREA UNITED PHARM, INC. Technical Analysis

Technical Analysis SentimentNegative
Last Price15590.00

Price Trends

50DMA17323.80Negative
100DMA17484.00Negative
200DMA18545.75Negative

Market Momentum

MACD-523.92Positive
RSI28.93Positive
STOCH12.65Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:033270, the sentiment is Negative. The current price of 15590.00 is below the 20-day moving average (MA) of 16425.00, below the 50-day MA of 17323.80, and below the 200-day MA of 18545.75, indicating a bearish trend. The MACD of -523.92 indicates Positive momentum. The RSI at 28.93 is Positive, neither overbought nor oversold. The STOCH value of 12.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:033270.

KOREA UNITED PHARM, INC. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

KR:033270 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
KR:096760KR:09676072OutperformKRW 256.35B3.04―5.80%10.18%149.93%
KR:033270KR:03327071OutperformKRW 226.20B4.36―3.91%0.85%25.23%
KR:003120KR:00312066NeutralKRW 93.64B36.24―5.77%-5.16%-53.05%
KR:008490KR:00849062NeutralKRW 178.68B4.87―3.11%9.19%-6.51%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
KR:009290KR:00929052NeutralKRW 294.94B24.97―1.59%5.20%-65.65%
KR:003520KR:00352040UnderperformKRW 145.40B-18.09――1.83%-860.37%

* General Sector Average

Performance Comparison

-50%0%50%KR:033270KR:003120KR:003520KR:008490KR:009290KR:096760Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
KR:033270 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
KR:033270KOREA UNITED PHARM, INC.15590.00-3188.72-16.98%
KR:003120ILSUNG IS CO., LTD.20800.00-943.36-4.34%
KR:003520YUNGJIN PHARM. CO. LTD795.00-1187.00-59.89%
KR:008490Suheung Co. Ltd.16070.00-6979.88-30.28%
KR:009290Kwang Dong Pharmaceutical Co., Ltd.6270.00428.017.33%
KR:096760JW Holdings Corporation3705.00421.1612.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026